Will NICE Change Its Mind On Scenesse After UK Public Hearing?

This month should see the outcome of a public hearing held to discuss the decision by the UK's health technology assessment body, NICE, not to recommend funding for Clinuvel’s Scenesse, a novel treatment for the ultra-rare condition, erythropoietic protoporphyria.

Appeal
Clinuvel and patient groups are awaiting the outcome of their appeals against NICE's rejection of Scenesse • Source: Shutterstock

Clinuvel and patient groups in the UK expect to find out this month whether a public hearing on NICE’s decision to recommend against funding the phototoxicity drug Scenesse (afamelanotide) has persuaded the health technology assessment institute to change its mind.

The hearing was held after the company and a number of patient and medical bodies lodged appeals against a decision...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet